| Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. | |
MedLine Citation:
|
PMID: 11961051 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ventricular administration of the opioid dynorphin A(1-17) induces feeding in rats. Because its pharmacological characterization has not been fully identified, the present study examined whether a dose-response range of general and selective opioid antagonists as well as antisense oligodeoxynucleotide (AS ODN) opioid probes altered daytime feeding over a 4-h time course elicited by dynorphin. Dynorphin-induced feeding was significantly reduced by a wide range of doses (5-80 nmol i.c.v.) of the selective kappa(1)-opioid antagonist nor-binaltorphamine. Correspondingly, AS ODN probes directed against either exons 1 and 2, but not 3 of the kappa-opioid receptor clone (KOR-1) reduced dynorphin-induced feeding, whereas a missense oligodeoxynucleotide control probe was ineffective. Furthermore, AS ODN probes directed against either exons 1 or 2, but not 3 of the kappa(3)-like opioid receptor clone (KOR-3/ORL-1) also attenuated dynorphin-induced feeding. Although the selective mu-antagonist beta-funaltrexamine (20-80 nmol) reduced dynorphin-induced feeding, an AS ODN probe directed only against exon 1 of the mu-opioid receptor clone was transiently effective. Neither general (naltrexone, 80 nmol) nor delta (naltrindole, 80 nmol)-selective opioid antagonists were particularly effective in reducing dynorphin-induced feeding, and an AS ODN probe targeting the individual exons of the delta-opioid receptor clone failed to significantly reduce dynorphin-induced feeding. These converging antagonist and AS ODN data firmly implicate the kappa(1)-opioid receptor and the KOR-1 and KOR-3/ORL-1 opioid receptor genes in the mediation of dynorphin-induced feeding. |
Authors:
|
Robert M Silva; Henya C Grossman; Maria M Hadjimarkou; Grace C Rossi; Gavril W Pasternak; Richard J Bodnar |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: The Journal of pharmacology and experimental therapeutics Volume: 301 ISSN: 0022-3565 ISO Abbreviation: J. Pharmacol. Exp. Ther. Publication Date: 2002 May |
Date Detail:
|
Created Date: 2002-04-18 Completed Date: 2002-05-13 Revised Date: 2014-04-08 |
Medline Journal Info:
|
Nlm Unique ID: 0376362 Medline TA: J Pharmacol Exp Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 513-8 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Dose-Response Relationship, Drug Drug Interactions Dynorphins / pharmacology* Feeding Behavior / drug effects* Male Models, Animal Naltrexone / analogs & derivatives*, pharmacology Narcotic Antagonists / pharmacology* Oligonucleotides, Antisense / pharmacology* Rats Rats, Sprague-Dawley Receptors, Opioid / antagonists & inhibitors*, metabolism Receptors, Opioid, delta / antagonists & inhibitors, metabolism Receptors, Opioid, kappa / antagonists & inhibitors, metabolism Receptors, Opioid, mu / antagonists & inhibitors, metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
DA00220/DA/NIDA NIH HHS; DA00310/DA/NIDA NIH HHS; DA07274/DA/NIDA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Narcotic Antagonists; 0/Oligonucleotides, Antisense; 0/Receptors, Opioid; 0/Receptors, Opioid, delta; 0/Receptors, Opioid, kappa; 0/Receptors, Opioid, mu; 105618-26-6/norbinaltorphimine; 111555-53-4/naltrindole; 5S6W795CQM/Naltrexone; 72782-05-9/beta-funaltrexamine; 74913-18-1/Dynorphins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk f...
Next Document: Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol...